Evonetix is revolutionizing gene synthesis with the aim of producing DNA at scale to enable many applications in the rapidly growing field of synthetic biology, across a wide range of industries, from pharmaceuticals to industrial biotech, specialty chemicals, renewables, bioremediation, agriculture and potentially also digital data storage. The company’s platform is based upon a novel silicon array and unique synergistic thermal control chemistry, capable of synthesizing oligonucleotides in parallel, at each of the 10,000 miniaturized reaction sites.




d Paul Beastall, Acting CEO & Board Chair

Matthew Hayes, CTO

Raquel Sanches-Kuiper, VP of Technology